Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in postoperative supraventricular tachyarrhythmias.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ONO-1101 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients who met the heart rate reduction criteria (20% reduction from the baseline heart rate and a heart rate of <100 beats/min) |
| Measure | Description | Time Frame |
|---|---|---|
| Heart rate, blood pressure, rate-pressure-product and ECG |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Project Leader, Development Planning | Ono Pharmaceutical Co., Ltd. | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| C077049 | landiolol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided